Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets.
Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets.
复制标题
DOI：
10.1016/j.bmcl.2013.02.014
复制
发表时间：
2013-04-01
影响因子：
2.7
通讯作者：
McAlpine, Shelli R.
中科院分区：
文献类型：
--
作者：
McConnell, Jeanette R.;McAlpine, Shelli R.
热休克蛋白在癌症的发展中起着至关重要的作用，是主要的治疗靶点。与使用单一疗法相比，在双重疗法中针对多种热休克蛋白可降低耐药的可能性。此外，将一种热休克蛋白抑制剂与另一种疗法联合使用在临床上已被证明是成功的。有效的策略包括抑制hsp27，防止蛋白质聚集，控制hsp40作为atp酶调节剂的作用，以及抑制hsp70作为分子伴侣的作用。虽然hsp40疗法还处于起步阶段，但hsp27和hsp70疗法已经成功地用于hsp90抑制剂的双重抑制治疗以及与抗肿瘤药物的联合治疗。当用于治疗化疗耐药疾病时，双重和联合疗法都显示出令人鼓舞的结果。
The heat shock proteins are essential players in the development of cancer and they are prime therapeutic targets. Targeting multiple hsps in dual therapies decreases the likelihood of drug resistance compared to utilizing mono-therapies. Further, employing an hsp inhibitor in combination with another therapy has proven clinically successful. Examples of efficacious strategies include the inhibition of hsp27, which prevents protein aggregation, controlling hsp40’s role as an ATPase modulator, and inhibiting hsp70 from acting as a molecular chaperone. While hsp40 therapies are just in the beginning stages, hsp27 and hsp70 therapies have been successfully used in dual inhibition treatments with hsp90 inhibitors and in combinational therapy with antineoplastic drugs. Both dual and combinatorial therapies show encouraging results when used in treating chemotherapeutically resistant diseases.
登录
查看更多内容
影响因子：
3.7
作者：
Chen SF;Tsai HJ;Hung TH;Chen CC;Lee CY;Wu CH;Wang PY;Liao NC
通讯作者：
Liao NC
影响因子：
3.8
作者：
Kang SH;Kang KW;Kim KH;Kwon B;Kim SK;Lee HY;Kong SY;Lee ES;Jang SG;Yoo BC
通讯作者：
Yoo BC
影响因子：
8
作者：
Gibert, B.;Hadchity, E.;Diaz-Latoud, C.
通讯作者：
Diaz-Latoud, C.
影响因子：
--
作者：
Braunstein MJ;Scott SS;Scott CM;Behrman S;Walter P;Wipf P;Coplan JD;Chrico W;Joseph D;Brodsky JL;Batuman O
通讯作者：
Batuman O
影响因子：
15
作者：
Cho, Hyungseoph J.;Gee, Heon Yung;Shin, Injae
通讯作者：
Shin, Injae